BCZ

3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID

Find entries where: BCZ

is present as a standalone ligand in 11 entries

Find related ligands:

Chemical Component Summary
Name	3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID
Synonyms	BCX-1812
Identifiers	(1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-carbamimidamido-2-hydroxy-cyclopentane-1-carboxylic acid
Formula	C₁₅ H₂₈ N₄ O₄
Molecular Weight	328.407
Type	NON-POLYMER
Isomeric SMILES	CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)NC(=N)N)NC(=O)C
InChI	InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1
InChIKey	XRQDFNLINLXZLB-CKIKVBCHSA-N

Chemical Details
Formal Charge	0
Atom Count	51
Chiral Atom Count	5
Bond Count	51
Aromatic Bond Count	0

Drug Info: DrugBank

DrugBank ID	DB06614 ?
Name	Peramivir
Groups	approved investigational
Description	Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.
Synonyms	Peramivir anhydrous Peramivir Peramivir hydrate
Brand Names	Rapivab Alpivab
Indication	Peramivir is indicated for the treatment of acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days.[L36768]
Categories	Amidines Anti-Infective Agents Antiinfectives for Systemic Use Antiviral Agents Antivirals for Systemic Use Direct Acting Antivirals Enzyme Inhibitors Neuraminidase Inhibitors Neuraminidase, antagonists & inhibitors
ATC-Code	J05AH03
CAS number	330600-85-6

Drug Targets

Name	Target Sequence	Pharmacological Action
Neuraminidase	MNPNQKILCTSATALVIGTIAVLIGITNLGLNIGLHLKPSCNCSHSQPEA...	unknown
Neuraminidase	MNPNQKIITIGSVSLTIATICFLMQIAILVTTVTLHFKQYECSSPPNNQV...	unknown
Neuraminidase	MLPSTIQTLTLFLTSGGVLLSLYVSASLSYLLYSDILLKFSSKITAPTMT...	unknown

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682